Answers are grounded in this paper and cite their sources.
In their Policy Forum “Moving toward transparency of clinical trials” (7 March, p. 1340), D. A. Zarin and T. Tse caution that “FDAAA 801 still leaves areas of 'opacity.'” We would like to point out another loophole: FDAAA 801 will only cover future drugs. The thousands of drugs on the market today, including the controversial examples cited by Zarin and Tse, will be grandfathered in and not covered.
No takes yet. Share an insight, caveat, or question.
Turner et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: